# Travere Therapeutics, Inc. (TVTX) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Travere Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/TVTX/mda/fy2025/): filed 2026-02-19; accession 0001438533-26-000014 (https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/TVTX/mda/fy2024/): filed 2025-02-21; accession 0001438533-25-000010 (https://www.sec.gov/Archives/edgar/data/1438533/000143853325000010/tvtx-20241231.htm)
- [FY 2023 MD&A](/company/TVTX/mda/fy2023/): filed 2024-02-20; accession 0001438533-24-000005 (https://www.sec.gov/Archives/edgar/data/1438533/000143853324000005/tvtx-20231231.htm)
- [FY 2022 MD&A](/company/TVTX/mda/fy2022/): filed 2023-02-23; accession 0001438533-23-000008 (https://www.sec.gov/Archives/edgar/data/1438533/000143853323000008/tvtx-20221231.htm)
- [FY 2021 MD&A](/company/TVTX/mda/fy2021/): filed 2022-02-24; accession 0001438533-22-000008 (https://www.sec.gov/Archives/edgar/data/1438533/000143853322000008/rtrx-20211231.htm)

Back to /company/TVTX/